MX2023007780A - Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. - Google Patents
Terapia de combinacion usando un anticuerpo anti-fucosil-gm1.Info
- Publication number
- MX2023007780A MX2023007780A MX2023007780A MX2023007780A MX2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- fucosyl
- combination therapy
- subject
- lung cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135479P | 2021-01-08 | 2021-01-08 | |
| PCT/US2022/011564 WO2022150557A1 (en) | 2021-01-08 | 2022-01-07 | Combination therapy using an anti-fucosyl-gm1 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007780A true MX2023007780A (es) | 2023-07-10 |
Family
ID=80119207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007780A MX2023007780A (es) | 2021-01-08 | 2022-01-07 | Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240050564A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4274850A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024503379A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230129467A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116745322A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022205648A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3204392A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304200A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007780A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022150557A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201912657D0 (en) * | 2019-09-03 | 2019-10-16 | Scancell Ltd | Binding members |
| WO2026107143A1 (en) * | 2024-11-14 | 2026-05-21 | Bristol-Myers Squibb Company | Fixed dose combination of anti-fucosyl-gm1 antibody and anti-pd-1 antibody and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EA017491B1 (ru) | 2005-12-08 | 2012-12-28 | Медарекс, Инк. | Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US11104739B2 (en) * | 2016-04-14 | 2021-08-31 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody |
| WO2017210631A1 (en) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer |
| SG11201909064RA (en) * | 2017-03-30 | 2019-10-30 | Merck Patent Gmbh | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |
| TWI890148B (zh) * | 2018-06-23 | 2025-07-11 | 美商建南德克公司 | 以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法 |
-
2022
- 2022-01-07 US US18/271,579 patent/US20240050564A1/en active Pending
- 2022-01-07 EP EP22702075.7A patent/EP4274850A1/en active Pending
- 2022-01-07 MX MX2023007780A patent/MX2023007780A/es unknown
- 2022-01-07 JP JP2023541613A patent/JP2024503379A/ja active Pending
- 2022-01-07 CN CN202280009378.0A patent/CN116745322A/zh active Pending
- 2022-01-07 WO PCT/US2022/011564 patent/WO2022150557A1/en not_active Ceased
- 2022-01-07 KR KR1020237026366A patent/KR20230129467A/ko active Pending
- 2022-01-07 AU AU2022205648A patent/AU2022205648A1/en active Pending
- 2022-01-07 CA CA3204392A patent/CA3204392A1/en active Pending
-
2023
- 2023-07-03 IL IL304200A patent/IL304200A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022205648A9 (en) | 2024-09-19 |
| JP2024503379A (ja) | 2024-01-25 |
| KR20230129467A (ko) | 2023-09-08 |
| WO2022150557A1 (en) | 2022-07-14 |
| AU2022205648A1 (en) | 2023-08-24 |
| CA3204392A1 (en) | 2022-07-14 |
| US20240050564A1 (en) | 2024-02-15 |
| CN116745322A (zh) | 2023-09-12 |
| EP4274850A1 (en) | 2023-11-15 |
| IL304200A (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| SA522433129B1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| BR112018070636A2 (pt) | método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| PH12018502409A1 (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| MX2020008404A (es) | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). | |
| EA202190181A1 (ru) | Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1 | |
| AU2017228470A8 (en) | Combination therapy with anti-CD73 antibodies | |
| MX2025001102A (es) | Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX2022001165A (es) | Composiciones terapeuticas, combinaciones y metodos de uso. | |
| PH12017501748A1 (en) | Antibodies to icos | |
| JOP20230118A1 (ar) | مركب كربوكساميد أريل غير متجانس | |
| ZA201907135B (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| MX393974B (es) | Terapia de combinacion para tratamiento de cancer. | |
| WO2016029073A3 (en) | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| MX2024006765A (es) | Terapia de combinación con adc ceacam5 - anti-pd1/pd-l1. | |
| MX2019002728A (es) | Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres. | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MX2023003186A (es) | Regimenes de dosificacion de anticuerpo anti-ilt4 o su combinacion con anticuerpo anti-pd-1 para el tratamiento de cancer. | |
| WO2021062085A8 (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| WO2022212400A8 (en) | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy | |
| MX2021000558A (es) | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino. |